"It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer

Seminars in Immunology

Volumn 20, Issue 5, 2008, Pages 296-300

  Buckwalter, Matthew R ^a   Srivastava, Pramod K ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer vaccines; Heat shock proteins; Melanoma; Personalized treatment; Renal cell carcinoma; Shared antigens; Unique antigens

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CD20 ANTIBODY; DACARBAZINE; GLYCOPROTEIN GP 96; INTERLEUKIN 2; TEMOZOLOMIDE; TUMOR ANTIGEN;

B CELL LYMPHOMA; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER MODEL; CLINICAL TRIAL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; KIDNEY CARCINOMA; MELANOMA; METASTASIS; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PROPHYLAXIS; PROSTATE CANCER; REVIEW; T LYMPHOCYTE; TIME;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNE SYSTEM; NEOPLASMS;

EID: 55549110891     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2008.07.003     Document Type: Review

References (56)

1. Meeker T.C., Lowder J., Maloney D.G., Miller R.A., Thielemans K., Warnke R., et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65 (1985) 1349-1363
2. McLaughlin P., Grillo-López A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 August (8) (1998) 2825-2833
3. Horowitz M.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 February 1 (3) (1990) 555-562
4. Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17 July (7) (1999) 2105-2116
5. McDermott D.F., Regan M.M., Clark J.I., Flaherty L.E., Weiss G.R., Logan T.F., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 January (1) (2005) 133-141 [Erratum in: J Clin Oncol. 2005;23(April 20 (12)):2877]
6. Gogas H., Ioannovich J., Dafni U., Stavropoulou-Giokas C., Frangia K., Tsoutsos D., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354 February 16 (7) (2006) 709-718
7. Tamura Y., Peng P., Liu K., Daou M., and Srivastava P.K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278 October 3 (5335) (1997) 117-120 [Erratum in: Science 1999;283(February 19 (5405)):preceding 1119]
8. Finkelstein S.E., Heimann D.M., Klebanoff C.A., Antony P.A., Gattinoni L., Hinrichs C.S., et al. Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. J Leukoc Biol 76 August (2) (2004) 333-337
9. Kovalchin J.T., Murthy A.S., Horattas M.C., Guyton D.P., and Chandawarkar R.Y. Determinants of efficacy of immunotherapy with tumor-derived heat shock protein gp96. Cancer Immun 1 April 27 (2001) 7
10. Heckman K.L., Schenk E.L., Radhakrishnan S., Pavelko K.D., Hansen M.J., and Pease L.R. Fast-tracked CTL: rapid induction of potent anti-tumor killer T cells in situ. Eur J Immunol 37 July (7) (2007) 1827-1835
11. Parsa A.T., Waldron J.S., Panner A., Crane C.A., Parney I.F., Barry J.J., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13 January (1) (2007) 84-88
12. Gingrich J.R., Barrios R.J., Morton R.A., Boyce B.F., DeMayo F.J., Finegold M.J., et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 56 September 15 (18) (1996) 4096-4102
13. Cardiff R.D., Moghanaki D., and Jensen R.A. Genetically engineered mouse models of mammary intraepithelial neoplasia. J Mammary Gland Biol Neoplasia 5 October (4) (2000) 421-437
14. Vargo-Gogola T., and Rosen J.M. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 7 September (9) (2007) 659-672
15. Scaglione B.J., Salerno E., Balan M., Coffman F., Landgraf P., Abbasi F., et al. Murine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand Black mouse model. Br J Haematol 139 December (5) (2007) 645-657
16. Hanahan D., Wagner E.F., and Palmiter R.D. The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev 21 September 15 (18) (2007) 2258-2270
17. Frese K.K., and Tuveson D.A. Maximizing mouse cancer models. Nat Rev Cancer 7 September (9) (2007) 645-658
18. Database of human tumor antigens recognized by T cells. Istituto Nazionale per lo Studio e la Cura dei Tumori (INT)-Milan, Italy. http://www.istitutotumori.mi.it/INT/AreaProfessionale/Human_Tumor/default.asp?LinkAttivo=17B.
19. Cancer/testis (CT) Gene Database, Ludwig Institute for Cancer Research, Office of Information Technology-Lausanne, Switzerland http://www.cancerimmunity.org/CTdatabase/.
20. Rosenberg S.A., Sherry R.M., Morton K.E., Scharfman W.J., Yang J.C., Topalian S.L., et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 175 November 1 (9) (2005) 6169-6176
21. Srivastava P.K. Immunotherapy of human cancer: lessons from mice. Nature Immunol 1 November 1 (5) (2000) 363-366
22. Srivastava P.K. Do human cancers express shared protective antigens? or the necessity of remembrance of things past. Semin Immunol 8 October (5) (1996) 295-302
23. Baurain J.F., Colau D., van Baren N., Landry C., Martelange V., Vikkula M., et al. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. J Immunol 164 (2000) 6057-6066
24. Chiari R., Foury F., De Plaen E., Baurain J.-F., Thonnard J., and Coulie P.-G. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res 59 (1999) 5785-5792
25. Coulie P.G., Lehmann F., Lethe B., Herman J., Lurquin C., Andrawiss M., et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci 92 (1995) 7976-7980
26. Dubey P., Hendrickson R.C., Meredith S.C., Siegel C.T., Shabanowitz J., Skipper J.C.A., et al. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med 185 (1997) 695-706
27. Echchakir H., Mami-Chouaib F., Vergnon I., Baurain J.-F., Karanikas V., Chouaib S., et al. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 61 (2001) 4078-4083
28. Ikeda H., Ohta N., Furukawa K., Miyazaki H., Wang L., Furukawa K., et al. Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma. Proc Natl Acad Sci 94 (1997) 6375-6379
29. Karanikas V., Colau D., Baurain J.-F., Chiari R., Thonnard J., Gutierrez-Roelens I., et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 61 (2001) 3718-3724
30. Lennerz V., Fatho M., Gentilini C., Frye R.A., Lifke A., Ferel D., et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci 102 (2005) 16013-16018
31. Matsutake T., and Srivastava PK. The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein. Proc Natl Acad Sci 98 (2001) 3992-3997
32. Monach P.A., Meredith S.C., Siegel C.T., and Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity 2 (1995) 45-59
33. Sensi M., Nicolini G., Zanon M., Colombo C., Molla A., Bersani I., et al. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8+ T cells with a memory phenotype. Cancer Res 65 (2005) 632-64024
34. Takenoyama M., Baurain J.-F., Yasuda M., So T., Sugaya M., Hanagiri T., et al. A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer 118 (2006) 1992-1997
35. Zorn E., and Hercend T. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol 29 (1999) 592-601
36. Srivastava P.K. Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. Adv Cancer Res 62 (1993) 153-177
37. Srivastava P.K., and Old L.J. Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today 9 March (3) (1988) 78-83
38. Mumberg D., Wick M., and Schreiber H. Unique tumor antigens redefined as mutant tumor-specific antigens. Semin Immunol 8 October (5) (1996) 289-293
39. Srivastava P.K., Udono H., Blachere N.E., and Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39 2 (1994) 93-98
40. Binder R.J., Blachere N.E., and Srivastava P.K. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J Biol Chem 276 May 18 (20) (2001) 17163-17171
41. Kunisawa J., and Shastri N. The group II chaperonin TRiC protects proteolytic intermediates from degradation in the MHC class I antigen processing pathway. Mol Cell 12 September 3 (2003) 565-576
42. Kunisawa J., and Shastri N. Hsp90alpha chaperones large C-terminally extended proteolytic intermediates in the MHC class I antigen processing pathway. Immunity 24 May (5) (2006) 523-534
43. Callahan M.K., Garg M., and Srivastava P.K. Heat-shock protein 90 associates with N-terminal extended peptides and is required for direct and indirect antigen presentation. Proc Natl Acad Sci USA 105 February 5 (5) (2008) 1662-1667
44. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20 (2002) 395-425
45. Testori A., Richards J., Whitman E., Mann G.B., Lutzky J., Camacho L., et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma. J Clin Oncol 26 February 20 (6) (2008) 955-962
46. Wood C., Srivastava P., Bukowski R., Lacombe L., Gorelov A.I., Gorelov S., Mulders P., Zielinski H., Hoos A., Teofilovici F., Isakov L., Flanigan R., Figlin R., Gupta R., and Escudier B. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 372 9633 (2008 Jul 12) 145-154
47. Gilboa E., and Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev June (199) (2004) 251-263
48. Kyte J.A., and Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother 55 November (11) (2006) 1432-1442
49. Ramarathinam L., Sarma S., Maric M., Zhao M., Yang G., Chen L., et al. Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J Immunol 155 December (11) (1995) 5323-5329
50. Sarma S., Bai X.F., Liu J.Q., May Jr. K.F., Zheng P., and Liu Y. On the role of unmutated antigens in tumor rejection in mice with unperturbed T-cell repertoires. Cancer Res 63 September 15 (18) (2003) 6051-6055
51. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100 April 15 (8) (2003) 4712-4717
52. Hodi F.S., Butler M., Oble D.A., Seiden M.V., Haluska F.G., Kruse A., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105 February 26 (8) (2008) 3005-3010
53. Garin-Chesa P., Old L.J., and Rettig W.J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 87 September (18) (1990) 7235-7239
54. Singh S., Ross S.R., Acena M., Rowley D.A., and Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med 175 January 1 (1) (1992) 139-146
55. Yu P., Rowley D.A., and Fu Y.X. Schreiber. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol 18 April (2) (2006) 226-231
56. Waldmann T.A. Effective cancer therapy through immunomodulation. Annu Rev Med 57 (2006) 65-81